# RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL

> **NCT05425654** · PHASE2 · RECRUITING · sponsor: **National Research Center for Hematology, Russia** · enrollment: 30 (estimated)

## Conditions studied

- Primary CNS Lymphoma

## Interventions

- **DRUG:** Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide

## Key facts

- **NCT ID:** NCT05425654
- **Lead sponsor:** National Research Center for Hematology, Russia
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-17
- **Primary completion:** 2023-05
- **Final completion:** 2026-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05425654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05425654, "RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05425654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*